Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2023-178017

Published: 2023

Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana

Blood (2023) 142 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2023-177989

Published: 2023

Journal Articles

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz, Steven M Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales

Blood (2022) 140 (Supplement 1): 10833–10834.

https://doi.org/10.1182/blood-2022-157439

Published: 2022

Journal Articles

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

M. Lia Palomba, MD, Monika P. Jun, MPH, Jacob Garcia, MD, James Lymp, PhD, November McGarvey, Matthew Gitlin, Corey Pelletier, Andy Nguyen

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-141415

Published: 2020

Journal Articles

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Mark Acosta, PharmD, Arrash Darban, PharmD, MS, Matthew Gitlin, PharmD

Blood (2019) 134 (Supplement_1): 5869.

https://doi.org/10.1182/blood-2019-124990

Published: 2019

Journal Articles

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Tanya Siddiqi, MD, Jacob Garcia, MD, Christine Dehner, Andy Nguyen, PhD, Matthew Gitlin, PharmD, Karen C. Chung, PharmD, MS, Jeremy S. Abramson, MD MMSc

Blood (2018) 132 (Supplement 1): 319.

https://doi.org/10.1182/blood-2018-99-112214

Published: 2018

NARROW

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Email alerts

ASH Publications

American Society of Hematology

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Logistical Considerations Related to Melphalan As a Conditioning Agent in Autologous Stem Cell Transplant for Multiple Myeloma: Results of a Survey of Oncology Pharmacists, Nurses and Pharmacy Technicians

Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only